<DOC>
	<DOCNO>NCT00011895</DOCNO>
	<brief_summary>The purpose study determine effect treatment Trizivir ( TZV ) plus efavirenz ( EFV ) TZV alone viral load ( level HIV blood ) .</brief_summary>
	<brief_title>Safety Effectiveness TRIZIVIR ( Abacavir/Lamivudine/Zidovudine ) With Efavirenz HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs</brief_title>
	<detailed_description>Patients receive TZV plus EFV 48-week Induction Phase . Eligible patient , define plasma HIV-1 RNA 50 copies/ml , participate 48-week Maintenance Phase . Patients randomize equally receive either TZV plus EFV TZV alone . An immunology substudy conduct , include approximately first 100 patient enrol agree participate .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are least 13 year old . Are HIVpositive . Have viral load least 5,000 copies/ml . Agree use adequate reliable method birth control . Note : Hormonal birth control consider adequate . Provide write consent parent guardian , 18 year age . Exclusion Criteria Patients eligible study : Have take nonnucleoside reverse transcriptase inhibitor . Have take antiHIV drug 2 week . Have opportunistic ( AIDSrelated ) infection . Are pregnant breastfeeding . Have hepatitis within past 6 month . Are allergic study drug ingredient . Have mental , physical , substance abuse disorder . Have serious medical condition , diabetes , congestive heart failure , heart disease . Have gastrointestinal disorder affect drug absorption make difficult take medication mouth . Have receive within 4 week study entry , may require study period , radiation therapy , chemotherapy , drug affect immune system ( steroid drug , interleukin , vaccine , interferon ) . Have receive HIV vaccine within 3 month study entry , schedule receive one study period . Require foscarnet drug show effective HIV . Are take astemizole , cisapride , midazolam , triazolam , ergot derivative . Are take experimental drug . Are unlikely complete study take drug .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2002</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Drug Combinations</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>abacavir</keyword>
	<keyword>efavirenz</keyword>
</DOC>